IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2018

Current Status of Biological Therapies for the Treatment of Metastatic Melanoma. T. TANG, R. ELDABAJE, L. YANG (San Francisco, CA, USA). Anticancer Res 36:3229-3241,2016.
Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown, PA, USA). Anticancer Res 36:2085-2095,2016.
The NFĸB Signaling Pathway in Papillomavirus-induced Lesions: Friend or Foe? R.M. GIL DA COSTA, M.M.S.M. BASTOS, R. MEDEIROS, P.A. OLIVEIRA (Porto; Vila Real, Portugal). Anticancer Res 36:2073-2083,2016.
Methods to Increase Future Liver Remnant Volume in Patients with Primarily Unresectable Colorectal Liver Metastases: Current State and Future Perspectives. V. TRESKA (Pilsen, Czech Republic). Anticancer Res 36:2065-2071,2016.
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. A. GADDUCCI, M.E. GUERRIERI (Pisa, Italy). Anticancer Res 36:2055-2064,2016.
Refining the Performance of Sentinel Lymph Node Biopsy Postneoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice. H.E.H. CHEHADE, H. HEADON, A. KASEM, K. MOKBEL (London, UK). Anticancer Res 36:1461-1471,2016.
From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives. M. ROMANO, F. DE FRANCESCO, L. ZARANTONELLO, C. RUFFOLO, G.A. FERRARO, G. ZANUS, A. GIORDANO, N. BASSI, U. CILLO (Padua; Naples; Treviso; Siena, Italy; Philadelphia, PA, USA). Anticancer Res 36:1447-1460,2016.
Extracorporeal Photopheresis for Non-skin GvHD. J. BITTENBRING, J. REICHRATH (Homburg, Germany). Anticancer Res 36:1395-1396,2016.
Light - Instead of UV Protection: New Requirements for Skin Cancer Prevention. L. ZASTROW, J. LADEMANN (Berlin, Germany). Anticancer Res 36:1389-1393,2016.
Vitamin D and Mortality. S. PILZ, M. GRÜBLER, M. GAKSCH, V. SCHWETZ, C. TRUMMER, B.Ó. HARTAIGH, N. VERHEYEN, A. TOMASCHITZ, W. MÄRZ (Graz; Bad Aussee, Austria; Amsterdam, the Netherlands; Bern, Switzerland; New York, NY; New Haven, CT, USA; Mannheim, Germany). Anticancer Res 36:1379-1387,2016.
Photocarcinogenesis and Skin Cancer Prevention Strategies. C. SEEBODE, J. LEHMANN, S. EMMERT (Rostock; Goettingen, Germany). Anticancer Res 36:1371-1378,2016.
Roles of Solar UVB and Vitamin D in Reducing Cancer Risk and Increasing Survival. W.B. GRANT (San Francisco, CA, USA). Anticancer Res 36:1357-1370,2016.
Tumour–Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis. B.M. LOPES-BASTOS, W.G. JIANG, J. CAI (Cardiff, UK). Anticancer Res 36:1119-1126,2016.
Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer. S. JIA, J. CAI (Cardiff, UK; Beijing, PR China). Anticancer Res 36:1111-1118,2016.
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer. W. JIA, Y. FENG, A.J. SANDERS, E.L. DAVIES, W.G. JIANG (Cardiff, UK; Guangzhou, PR China). Anticancer Res 36:1103-1109,2016.
Biomarkers in Colorectal Cancer. A.J. YIU, C.Y. YIU (London, UK). Anticancer Res 36:1093-1102,2016.
Anticancer Properties of Capsaicin Against Human Cancer. R. CLARK, S.-H. LEE (College Park, MD, USA). Anticancer Res 36:837-843,2016.
Human Papillomavirus as a Diagnostic and Prognostic Tool in Cancer of Unknown Primary in the Head and Neck Region. L. SIVARS, E. TANI, A. NÄSMAN, T. RAMQVIST, E. MUNCK-WIKLAND, T. DALIANIS (Stockholm, Sweden). Anticancer Res 36:487-493. 2016.
TAS-102 an Emerging Oral Fluoropyrimidine. J. CHEN, M. HAN, M.W. SAIF (St. Lucia; Wollongong, Australia; Boston, MA, USA). Anticancer Res 36:21-26. 2016.
Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis. F. LUMACHI, G.B. CHIARA, R. TOZZOLI, A. DEL CONTEA, S.M.M. BASSO (Padova; Pordenone, Italy). Anticancer Res 36:13-19. 2016.
Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. A. DEVINE, L. MARIGNOL (Dublin, Ireland). Anticancer Res 36:5-12. 2016.
Using Epigenetic Therapy to Overcome Chemotherapy Resistance. J. STRAUSS, W.D. FIGG (Bethesda, MD, USA). Anticancer Res 36:1-4. 2016.
Innovative Therapeutic Strategies in the Treatment of Meningioma. G. CARUSO, S.K. ELBABAA, P. GONZALEZ-LOPEZ, V. BARRESI, M. PASSALACQUA, M. CAFFO (Messina, Italy; Saint Louis, MO, USA; Alicante, Spain). Anticancer Res 35: 6391-6400. 2015
Extracellular Vesicles as Biomarkers and Therapeutic Targets in Breast Cancer. L. SADOVSKA, J. EGLĪTIS, A. LINĒ (Riga, Latvia). Anticancer Res 35: 6379-6390. 2015
Curcumin for the Treatment of Glioblastoma. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown PA, USA). Anticancer Res 35: 6373-6378. 2015
Increased Production of Lysozyme Associated with Bacterial Proliferation in Barrett’s Esophagitis, Chronic Gastritis, Gluten-induced Atrophic Duodenitis (Celiac Disease), Lymphocytic Colitis, Collagenous Colitis, Ulcerative Colitis and Crohn’s Colitis. C.A. RUBIO (Stockholm, Sweden). Anticancer Res 35: 6365-6372. 2015
Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J. PINILLA- IBARZ, K. SWEET, J. EMOLE, M. FRADLEY (Tampa, FL, USA). Anticancer Res 35: 6355-6364. 2015
Primary Breast Cancer with Synchronous Metastatic Disease – Indications for Local Radiotherapy to the Breast and Chest Wall. S. JANSSEN, D. RADES (Hannover; Lubeck, Germany). Anticancer Res 35: 5807-5812. 2015
Brain Metastases in NSCLC – Are TKIs Changing the Treatment Strategy? W.C.M. DEMPKE, K. EDVARDSEN, S. LU, N. REINMUTH, M. RECK, A. INOUE (Cambridge, UK; Munich; Grosshansdorf, Germany; Shanghai, PR China; Sendai, Japan). Anticancer Res 35: 5797-5806. 2015
Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding the Anticancer Effect of Metformin and Its Clinical Implications. M. CAZZANIGA, B. BONANNI (Milan, Italy). Anticancer Res 35: 5789-5796. 2015
Natural Products That Target Cancer Stem Cells. J. MOSELHY, S. SRINIVASAN, M.K. ANKEM, C. DAMODARAN (Louisville, KY, USA). Anticancer Res 35: 5773-5788. 2015
Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. G.V. SHERBET (Huntington Beach, CA, USA; Newcastle, UK). Anticancer Res 35: 5767-5772. 2015
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST? I. HOMPLAND, Ø.S. BRULAND (Oslo, Norway). Anticancer Res 35: 5759-5765. 2015
Immunotherapies for NSCLC: Are We Cutting the Gordian Helix? W.C.M. DEMPKE, L. SELLMANN, K. FENCHEL, K. EDVARDSEN (Munich; Mönchengladbach; Hamburg, Germany; Cambridge, UK). Anticancer Res 35: 5745-5757. 2015
Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. M. STOTZ, A. GERGER, J. HAYBAECK, T. KIESSLICH, M.D. BULLOCK, M. PICHLER (Graz; Salzburg, Austria; Houston, TX, USA). Anticancer Res 35: 5737-5744. 2015
Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy. M. KOCH, A.J. FREUNDL, A. AGAIMY, F. KIESEWETTER, J. KÜNZEL, I. CICHA, C. ALEXIOU (Erlangen; Mainz, Germany). Anticancer Res 35: 5717-5735. 2015
Primary Thyroid Sarcoma: A Systematic Review. A. SUROV, S. GOTTSCHLING, A. WIENKE, H. JONAS MEYER, R.P. SPIELMANN, H. DRALLE (Halle-Wittenberg; Leipzig, Germany). Anticancer Res 35: 5185-5191. 2015
Predictive and Prognostic Value of the Tau Protein in Breast Cancer. C. BONNEAU, Z.A. GURARD-LEVIN, F. ANDRE, L. PUSZTAI, R. ROUZIER (Versailles; Paris, France; New Haven, CT, USA). Anticancer Res 35: 5179-5184. 2015
Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy. H. YAMAZAKI, S. NAKAMURA, G. SUZUKI, K. YOSHIDA, Y. YOSHIOKA, M. KOIZUMI, K. OGAWA (Kyoto; Takatsuki City; Suita, Japan). Anticancer Res 35: 5167-5177. 2015
Chronic Lymphocytic Leukemia: Current Concepts. E.-M. YU, A. KITTAI, I.A. TABBARA (Washington, DC, USA). Anticancer Res 35: 5149-5165. 2015
Nitric Oxide and Aggressive Behavior of Lung Cancer Cells. S. LUANPITPONG, P. CHANVORACHOTE (Bangkok, Thailand). Anticancer Res 35: 4585-4592. 2015
Second-line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives. P. CHROM, R. STEC, C. SZCZYLIK (Warsaw, Poland). Anticancer Res 35: 4575-4583. 2015
The Role of Methylation in Breast Cancer Susceptibility and Treatment. M.-C. POULIOT, Y. LABRIE, C. DIORIO, F. DUROCHER (Quebec, Canada). Anticancer Res 35: 4569-4574. 2015
Novel Molecular Targets for the Therapy of Urothelial Cancer. B.R.P. JANA, Y. ZHOU (Galveston, TX, USA). Anticancer Res 35: 4557-4567. 2015
Transcriptional Regulation of the p16 Tumor Suppressor Gene. Y. KOTAKE, M. NAEMURA, C. MURASAKI, Y. INOUE, H. OKAMOTO (Fukuoka, Japan). Anticancer Res 35: 4397-4401. 2015
Methods to Prevent or Treat Refractory Diseases by Focusing on Intestinal Microbes Using LPS and Macrophages. G.-I. SOMA, H. INAGAWA (Kagawa; Niigata, Japan). Anticancer Res 35: 4393-4396. 2015
Functional Alteration of Tumor-infiltrating Myeloid Cells in RNA Adjuvant Therapy. T. SEYA, H. SHIME, M. MATSUMOTO (Sapporo, Japan). Anticancer Res 35: 4385-4392. 2015
The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Ş. COMŞA, A.M. CÎMPEAN, M. RAICA (Timisoara, Romania). Anticancer Res 35: 3147-3154. 2015
Anticancer Effects of Sandalwood (Santalum album). S. SANTHA, C. DWIVEDI (Brookings, SD, USA). Anticancer Res 35: 3137-3145. 2015
Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer. C. DAMASKOS, T. KARATZAS, L. NIKOLIDAKIS, I.D. KOSTAKIS, S. KARAMAROUDIS, G. BOUTSIKOS, Z. DAMASKOU, A. KOSTAKIS, G. KOURAKLIS (Athens, Greece). Anticancer Res 35: 3129-3135. 2015
Page: 1 2 3 4 5 6 ... 7 8 9 10 11 12 
Custom Tables Plugin 05a1a29bdcae7b12229e651a9fd48b11

IMPORTANT NOTE: You may submit your article only through our online submission system